Semaglutide is a GLP-1 receptor–based medication that may be prescribed as part of a medically supervised program to support weight management and metabolic function. It is typically used alongside nutrition, physical activity, and lifestyle modifications.
Semaglutide may not be appropriate for individuals with:
A personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known hypersensitivity to semaglutide or its components
A comprehensive medical evaluation is required to determine if this therapy is appropriate.
Medications in this class have been associated with thyroid tumors in certain cases. Patients should be assessed for risk factors prior to starting therapy and monitored for symptoms such as a lump in the neck, difficulty swallowing, or persistent hoarseness.
Cases of acute pancreatitis have been reported with GLP-1–based therapies. Patients should be aware of symptoms such as severe abdominal pain (with or without vomiting) and seek immediate medical attention if they occur.
The risk of low blood sugar may increase when semaglutide is used in combination with insulin or medications that increase insulin production. Dose adjustments may be required.
Common gastrointestinal side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These symptoms are often temporary and may improve over time or with dose adjustments.
Changes in kidney function, including worsening of pre-existing conditions, have been reported. Monitoring may be recommended, particularly in individuals with known kidney disease.
Serious allergic reactions, including rash, swelling, or difficulty breathing, may occur. Discontinue use and seek medical attention if symptoms develop.
The most frequently reported side effects include:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Semaglutide is not recommended during pregnancy due to potential risk to the fetus. It is not known whether semaglutide is present in human breast milk. Individuals who are pregnant, planning to become pregnant, or breastfeeding should consult their provider before use.
Caution should be used when taking semaglutide with:
Medications that affect gastric emptying or absorption
Medications that increase the risk of hypoglycemia
Patients should inform their provider of all medications, supplements, and herbal products they are taking.
At Vybrant Health and Wellness, patients receiving semaglutide are monitored to support safety and effectiveness. This may include:
Clinical progress assessments
Metabolic and laboratory monitoring when appropriate
Ongoing evaluation of dosing and tolerability
Semaglutide therapy is prescribed as part of a comprehensive, individualized program that may include nutrition guidance, lifestyle support, and ongoing provider oversight.
Compounded semaglutide offered through our clinic is prepared by a licensed compounding pharmacy. These formulations are not FDA-approved and are prescribed based on individualized medical evaluation and clinical judgment.
This information is provided for educational purposes only and does not replace professional medical advice. Compounded semaglutide has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.